Loading
Zimmer Biomet Holdings, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 13 Nov 2023.
Zimmer Biomet Holdings, Inc.: what insiders have been doing
This page follows insider dealings at Zimmer Biomet Holdings, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Warsaw, United States. The group dates from 1927. From 18 October 2025 to 18 October 2026, the disclosure feed for Zimmer Biomet Holdings, Inc. logged 38 filings by 13 insiders.
No insider bought on the market over the period, while 3 insiders filed 3 sales totalling €552k. One trade stands out by size: a sale of €254k from Phipps Chad F, disclosed on 9 September 2026, or 0.0017% of market capitalisation.
Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Across the 5,808 companies tracked on its exchange, the median is 19 filings; at 38 filings, this issuer sits above that mark. Over the whole record (from 2016), the tally stands at 9 purchases and 30 sales. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 8.23 bn USD and net income at 705.1 m USD, and the dividend at 0.96 USD per share.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
153
Thresholds
n/a
Buy Volume
€1M
9 ops. · all time
Sell Volume
€3M
30 ops. · all time
Who traded when
BuySaleLori Winkler4 sales
Sang Yi4 sales
Chad F. Phipps1 sale
Thornal Kevin R1 sale
Since the insiders bought
- -3.1%Entry US$111.42 · Close at T+365 US$107.95
- -1.4%Entry US$117.81 · Close at T+365 US$116.17
- -3.1%Entry US$119.12 · Close at T+365 US$115.46
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Zimmer Biomet Holdings, Inc. Buy (bullish), based on 22 analysts. Average price target: US$106.82.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 8,285 of 24,148 companies
59.3
score / 100
Value61
Quality58
FCF yld7.8%
Earn yld3.9%
EV/EBITDA11.6x
ROE6.4%
Gross mgn70%
Net mgn8.6%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$92.08
Analyst consensus
22 analystsBuy
US$93.00Target US$106.82(+16%)US$130.00
Income statement
RevenueUS$8.2B
Gross profitUS$5.7B70% margin
EBITDAUS$2.2B27% margin
Net incomeUS$705.1M9.5% margin
Valuation
PER (trailing)22.3x
PER (forward)10.2x
P/Book1.4x
Beta0.49
Balance sheet & cash
Market capUS$17.6B
Total debtUS$7.5B
Free Cash FlowUS$1.4B
Debt / Equity60%
Profitability & ownership
ROE6.4%
ROA3.9%
% insiders0.2%
% institutions111.4%
Last declaration on 5 October 2026
Declarations153 total
2,368 shares0Common StockSEC:0002155115-26-000003:0
1,218 shares0Common StockSEC:0002155115-26-000003:2
932 shares@ US$88.420.0005% mcap66.0% of flowCommon StockSEC:0002155115-26-000003:1
480 shares@ US$88.420.0002% mcap34.0% of flowCommon StockSEC:0002155115-26-000003:3
5,691 shares@ US$92.950.0030% mcap57.0% of flowCommonSEC144:0001959173-26-006874
3,000 shares@ US$98.350.0017% mcap3.6% of flowCommon StockSEC:0001346672-26-000010:0
3,000 shares@ US$98.35010.0017% mcap3.6% of flowCommonSEC144:0001959173-26-006759
9,957 shares0Common StockSEC:0001783992-26-000004:0
4,266 shares@ US$92.680.0023% mcap43.0% of flowCommon StockSEC:0001783992-26-000004:1
7,668 shares@ US$92.860.0041% mcap63.2% of flowCommonSEC144:0001959173-26-005253
4,560 shares@ US$90.0650.0023% mcap36.8% of flowCommonSEC144:0001959173-26-004849
1,677 shares@ US$90.67100.0% of flowCommon StockSEC:0002059755-26-000004:1
6,626 shares0Common StockSEC:0002059755-26-000004:0
2,650 shares@ US$94.6634.5% of flowCommon StockSEC:0001852191-26-000010:0
3,935 shares0Common StockSEC:0001852191-26-000008:0
24,436 shares0Common StockSEC:0001757216-26-000008:0
1,363 shares0Common StockSEC:0001714585-26-000008:0
4,692 shares0Common StockSEC:0001346672-26-000008:0
4,843 shares0Common StockSEC:0001864818-26-000008:0
10,217 shares0Common StockSEC:0001533149-26-000009:0
3,182 shares0Common StockSEC:0001864818-26-000006:0
820 shares0Common StockSEC:0001714585-26-000006:0
6,364 shares0Common StockSEC:0001533149-26-000007:0
25 of 153 declarations
About Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. (ticker: ZBH) is a global medical technology company focused on orthopedics and musculoskeletal solutions. The stock is listed on the NYSE in the United States, and the company is headquartered in Warsaw, Indiana. Its roots date back to 1927, when Zimmer Manufacturing Company was founded in Warsaw. Zimmer Biomet became an independent public company in 2001 and later expanded materially through the 2015 acquisition of Biomet, which led to the current corporate name.
The company designs, manufactures and markets a broad portfolio of orthopedic implants and related devices, with core franchises in hips, knees and shoulders, as well as products for extremities, trauma, craniomaxillofacial and thoracic applications, bone cement, surgical products, and integrated digital and robotic technologies. Its offering includes robotic-assisted surgery platforms, navigation tools, software-enabled workflows and next-generation implant designs. For investors, Zimmer Biomet is best viewed as a broad-based orthopedic platform rather than a single-product company: it serves orthopedic surgeons, hospitals, ambulatory surgery centers, distributors and purchasing groups across multiple geographies.
Read moreShow less
From a competitive standpoint, the company benefits from a long operating history, a recognized brand, a large installed customer base and a meaningful global manufacturing and R&D footprint. Zimmer Biomet operates roughly 300 facilities worldwide, with major activities in the United States, Switzerland, Ireland and China. Its annual report indicates that the United States accounts for about 58% of revenue, making the U.S. market central to both its commercial performance and its ongoing transformation of its domestic go-to-market model.
Recent developments have been strategically important. Zimmer Biomet reported 2025 net sales of $8.232 billion, supported by market growth, new product introductions and the acquisition of Paragon 28. In 2025, it also completed the acquisition of Monogram Technologies, expanding its robotics and digital ecosystem with a pathway toward more autonomous orthopedic technology. In early 2026, the company highlighted the launch and expansion of ROSA Knee with OptimiZe, together with new regulatory milestones in hip and knee implants. Overall, the investment case combines a defensive elective-procedure profile, strong innovation intensity and targeted M&A aimed at faster-growing orthopedic subsegments.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
